Abstract
Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), has demonstrated efficacy in patients with chronic and episodic migraine (CM and EM). Efficacy and tolerability of fremanezumab for migraine preventive treatment in Korean patients with CM and EM have been evaluated in two randomized, double-blind, placebo-controlled phase 2b/3 clinical studies and compared with data from pivotal phase 3 HALO CM and HALO EM studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
